Cargando…

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study

INTRODUCTION: There is a multitude of assays for the detection of circulating tumor cells (CTCs) but a very limited number of studies comparing the clinical relevance of results obtained with different test methods. The DETECT trial for metastatic breast cancer patients was designed to directly comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Volkmar, Riethdorf, Sabine, Rack, Brigitte, Janni, Wolfgang, Fasching, Peter A, Solomayer, Erich, Aktas, Bahriye, Kasimir-Bauer, Sabine, Pantel, Klaus, Fehm, Tanja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680931/ https://www.ncbi.nlm.nih.gov/pubmed/22894854 http://dx.doi.org/10.1186/bcr3243

Ejemplares similares

Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch(®) System and the AdnaTest(®)
por: Gorges, Tobias M., et al.
Publicado: (2016)

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Müller, Volkmar, et al.
Publicado: (2011)

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2017)

Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2018)

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT–PCR in patients with metastatic breast cancer
por: Van der Auwera, I, et al.
Publicado: (2010)

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2016)

Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
por: Fehm, Tanja, et al.
Publicado: (2009)

A Direct Comparison between the Lateral Magnetophoretic Microseparator and AdnaTest for Isolating Prostate Circulating Tumor Cells
por: Cho, Hyungseok, et al.
Publicado: (2020)

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2009)

Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression
por: Roth, Carina, et al.
Publicado: (2011)

The characterization of four gene expression analysis in circulating tumor cells made by Multiplex-PCR from the AdnaTest kit on the lab-on-a-chip Agilent DNA 1000 platform
por: Škereňová, Markéta, et al.
Publicado: (2016)

Circulating and Disseminated Tumor Cells in Breast Carcinoma: Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma – What is the Role of Liquid Biopsy in Breast Cancer?
por: Polasik, Arkadius, et al.
Publicado: (2017)

Circulating microRNAs: promising breast cancer biomarkers - authors' response
por: Roth, Carina, et al.
Publicado: (2011)

Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer
por: Roth, Carina, et al.
Publicado: (2010)

Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients
por: Huebner, Hanna, et al.
Publicado: (2018)

Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2012)

Circulating and Disseminated Tumour Cells in Breast Carcinoma: Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2016)

Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
por: Rack, Brigitte, et al.
Publicado: (2014)

Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance
por: Fehm, Tanja, et al.
Publicado: (2008)

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
por: Müller, V., et al.
Publicado: (2021)

Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis—Results from the Adjuvant SUCCESS A Trial
por: Trapp, Elisabeth K., et al.
Publicado: (2022)

Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment
por: Bredemeier, Maren, et al.
Publicado: (2016)

53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients
por: Schochter, Fabienne, et al.
Publicado: (2020)

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
por: Fehm, Tanja, et al.
Publicado: (2007)

Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2022)

AGO Algorithms for the Treatment of Breast Cancer: Update 2021
por: Schneeweiss, Andreas, et al.
Publicado: (2021)

Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients
por: Riethdorf, Sabine, et al.
Publicado: (2009)

Correction: Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2022)

Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer
por: Bredemeier, Maren, et al.
Publicado: (2017)

Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer
por: Aktas, Bahriye, et al.
Publicado: (2022)

Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer
por: Fehm, Tanja N., et al.
Publicado: (2022)

Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer
por: Fehm, Tanja N., et al.
Publicado: (2023)

Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2023)

Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer
por: Miller, M. Craig, et al.
Publicado: (2010)

A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation
por: Frithiof, Henrik, et al.
Publicado: (2015)

Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer
por: Müller, Volkmar, et al.
Publicado: (2022)

Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients
por: Alunni-Fabbroni, Marianna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4u63uskhrjckg7rqg2k0c1q9bg